Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial)

• Popat, R
• Brown, SR
• Flanagan, L
• Hall, A
• Gregory, W https://orcid.org/0000-0003-2641-8416
• Kishore, B
• Streetly, M
• Oakervee, H
• Yong, K
• Cook, G https://orcid.org/0000-0003-0223-3652
• Low, E
• Cavenagh, J
• Myeloma UK Early Phase Clinical Trial Network

© 2018 British Society for Haematology and John Wiley & Sons Ltd. This is the peer reviewed version of the following article: Popat, R, Brown, SR, Flanagan, L et al. (10 more authors) (2018) Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial). British Journal of Haematology. ISSN 0007-1048, which has been published in final form at https://doi.org/10.1111/bjh.15551. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Uploaded in accordance with the publisher's self-archiving policy.

• Published: 16 April 2019
• Published (online): 20 August 2018